KORU Medical Systems (KORU Medical Systems) Debt-to-Equity : 0.22 (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is KORU Medical Systems Debt-to-Equity?

KORU Medical Systems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.64 Mil. KORU Medical Systems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.53 Mil. KORU Medical Systems's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $19.12 Mil. KORU Medical Systems's debt to equity for the quarter that ended in Mar. 2024 was 0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for KORU Medical Systems's Debt-to-Equity or its related term are showing as below:

KRMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.1 Max: 0.22
Current: 0.22

During the past 13 years, the highest Debt-to-Equity Ratio of KORU Medical Systems was 0.22. The lowest was 0.00. And the median was 0.10.

KRMD's Debt-to-Equity is ranked worse than
50.78% of 709 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs KRMD: 0.22

KORU Medical Systems Debt-to-Equity Historical Data

The historical data trend for KORU Medical Systems's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KORU Medical Systems Debt-to-Equity Chart

KORU Medical Systems Annual Data

Trend

Feb14

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.01

0.02

0.16

0.22

KORU Medical Systems Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.15	0.15	0.17	0.22	0.22

Competitive Comparison of KORU Medical Systems's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KORU Medical Systems's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where KORU Medical Systems's Debt-to-Equity falls into.

KORU Medical Systems Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

KORU Medical Systems's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.792	+	3.653)	/	20.354
	=	0.22

KORU Medical Systems's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.642	+	3.53)	/	19.118
	=	0.22

KORU Medical Systems (NAS:KRMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

KORU Medical Systems Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of KORU Medical Systems's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

KORU Medical Systems (KORU Medical Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » KORU Medical Systems Inc (NAS:KRMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Corporate Drive, Mahwah, NJ, USA, 07430

Website

https://www.korumedical.com

KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on home and specialty infusion solutions. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Executives

Manko Joseph M. Jr.	10 percent owner	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Kenneth E Miller	officer: Chief Commercial Officer	26 MOUNTAINVIEW RD, WARREN NJ 07059
Edward Wholihan	director	C/O ALLENA PHARMACEUTICALS, INC., ONE NEWTOWN EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Linda M Tharby	officer: President and CEO	BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Robert Cascella	director	C/O HOLOGIC, INC., BEDFORD MA 01730
Lafrence Andrew D.c.	officer: Chief Financial Officer	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Thomas Edward Adams	officer: Interim CFO	524 WOODLAND AVENUE, BRIELLE NJ 08730
Brian Case	officer: Chief Technology Officer	424 CYPRUS CIR, LAKE VILLA IL 60046-8629
Shahriar Matin	director	96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Donna French	director	25 SEARSVILLE COURT, HILLSBOROUGH CA 94010
Donald B Pettigrew	officer: Pres./Chief Commercial Officer	7871 ENGEN LOOP, PARK CITY UT 84098
Karen Fisher	officer: CFO	24 CARPENTER ROAD, CHESTER NY 10918
Daniel S Goldberger	director	24 CARPENTER ROAD, CHESTER NY 10918
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Horton Freedom, L.p.	10 percent owner	1717 ARCH STREET, 37TH FLOOR, PHILADELPHIA PA 19103